• Zum Hauptinhalt springen
  • Zum Footer springen
  • Deutsch - de
  • English - en

    SyNergy - Mu...

    • About
      • About us
      • Our Measures
      • Members
      • Cluster Management
      •  PhD & Postdoc representatives
      • Scientific Advisory Board
      •  International cooperation partners
      • Timeline
      •  Media Kit
      • Contact
    • News & Events
      • News
      • Events
      • In the News
      • Open Positions
    • Research
      • Publications
      • Our Research Focus
      • Technology Hubs
      • Research Spotlight
      • Research Data Management
      • Sustainability Initiative
      •  Code of Conduct
    • Science & Society
      • For Schools & Students
      • Public Events
      • Podcasts
      • Videos
    • Support for Diversity & Equity
      • Newcomer Center
      • Gender Equality Program
      • Early Career Investigator Program
    1. Home
    2. News & Events
    3. News
    4. Heinrich Wieland Prize for Matthias Tschöp: Breakthrough in the battle against obesity and diabetes
    News | 19/10/2023 | Press Release, Award

    Heinrich Wieland Prize for Matthias Tschöp: Breakthrough in the battle against obesity and diabetes

    Worldwide, a growing number of people is affected by obesity. This often leads to diabetes, severe cardiovascular diseases, and many other complications. To combat this global health crisis, effective medicines are essential. Prof. Matthias Tschöp from Helmholtz Munich and the Technical University of Munich (TUM), a pioneer in this field, has deciphered the central mechanisms of weight regulation and developed medicines that treat or prevent obesity and its consequences more effectively than ever before. For his groundbreaking work, he will receive the €100,000 Heinrich Wieland Prize from the Boehringer Ingelheim Foundationin Munich on 19 October 2023.
    Boehringer Ingelheim Stiftung / (C) Axel Griesch (Boehringer Ingelheim Stiftung / (C) Axel Griesch (Photographer)
    Matthias Tschöp

    "We are confident that the new multi-receptor drugs have immense potential to stop the pandemic of obesity and Type-2 diabetes," says award-winner Prof. Matthias Tschöp, Scientific Director of Helmholtz Munich and Humboldt Professor at the Technical University of Munich (TUM).

    • Read the full press release on the website of Helmholtz Munich.

    Participating Universities
     LMU logo in white
     TUM logo in white
    Partner Institutions
     Logo DZNE in white
    Helmholtz Munich logo in white 
     Logo Max Planck Gesellschaft 

    SyNergy is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) within the framework of the German Excellence Strategy (EXC 2145 SyNergy – ID 390857198). The Excellence Strategy promotes outstanding research at German universities. 

    Contact

    Munich Cluster for Systems Neurology (SyNergy)

    Feodor-Lynen-Str. 17
    81377 Munich
    +49 (0)89 4400-46497
    yüubgybcјuipxјdhvWfulyzemi
    Editor login
    Imprint | Data-Safety